I tend to agree given the somewhat unique territory NEU is working in. Also, there are plenty of commercialised drugs out there worth a lot of money that have average efficacy, but average is considered better than nothing in their cases.
So I think NEU stands in a good position compared to many biotechs tackling competitive areas such as oncology etc. However, if good but not great results occur, I don't think it will put a fire under the SP until any concrete talk of pharma deals eventuate.
FDA meeting is today, page-12
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.33 |
Change
-0.480(3.48%) |
Mkt cap ! $1.703B | |||
| Open | High | Low | Value | Volume |
| $13.82 | $13.91 | $13.32 | $4.989M | 369.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.41 | 1680 | 2 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |